Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology
Importance To date, the benefit of genome-driven cancer therapy has not been quantified.
Objective We sought to estimate the annual percentage of patients in the United States with
advanced or metastatic cancer who could be eligible for and benefit from US Food and Drug
Administration (FDA)-approved genome-driven therapy from 2006 to 2018. Design, Setting,
and Participants Retrospective cross-sectional study using publically available data of (1)
demographic characteristics of patients with advanced or metastatic cancer;(2) FDA data on …
Objective We sought to estimate the annual percentage of patients in the United States with
advanced or metastatic cancer who could be eligible for and benefit from US Food and Drug
Administration (FDA)-approved genome-driven therapy from 2006 to 2018. Design, Setting,
and Participants Retrospective cross-sectional study using publically available data of (1)
demographic characteristics of patients with advanced or metastatic cancer;(2) FDA data on …
